At a glance
ClinicalIndex Comparison RecordN/ACompleted· 310 enrolled
Drug / intervention
No interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rhabdomyolysis - a Study of Patients and Laboratory Values to Guide Treatment
In Brief
An observational study evaluating No intervention for Rhabdomyolysis. Completed, enrolled 310 participants across 1 site.
Detailed Summary
Rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (CK) into the circulation. The aetiological spectrum of rhabdomyolysis is extensive, and the clinical spectrum varies from a transient subclinical increase in CK activity to acute kidney injury (AKI) as a serious complication. There are no large prospective studies and only a few retrospective studies on rhabdomyolysis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRhabdomyolysis
CountriesNorway
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartAug 2019
First PostedOct 2019
Primary CompletionDec 2023
TodayJul 2026
First PostedOct 8, 2019
Enrollment StartAug 4, 2019
Primary CompletionDec 22, 2023
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 6.7 years ago
Interventions
No interventionother
No intervention